Immune Responses With Reduxium
Study Details
Study Description
Brief Summary
Reduxium is a dietary supplement that provides immune support. This natural compound is orally-ingested in the form of droplets in water to boost the immune system and control inflammation. There is not enough data on the mechanism associated with the action of Reduxium or the extent of the immune response increase it produces. In this study, the investigators propose treating a group of healthy volunteers with Reduxium and investigate the utility of this approach in boosting the native and adaptive immune responses that correlate with immune protection. This may form the basis for a future study employing the product in infectious disease patients.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
With the global population increasingly exposed to pandemic crises, permanent and expedient solutions are needed at an affordable cost. Vaccination is less than ideal as the virus is prone to a mutation that renders the previous generation of vaccine less effective. Epidemic and pandemic of viruses infection has become more common and affects both developed and less developed communities. Overcrowding and poor hygiene have been cited to be the major factors in these epidemics, but the host immune system and the ability of the human system to ward off virus infection is a factor less mentioned.
Nutrition is a critical determinant of immune responses and malnutrition the most common cause of immunodeficiency worldwide. Protein-energy malnutrition is associated with a significant impairment of cell-mediated immunity, phagocyte function, complement system, secretory immunoglobulin A antibody concentrations, and cytokine production. Deficiency of single nutrients also results in altered immune responses: this is observed even when the deficiency state is relatively mild. Of the micronutrients, zinc; selenium; iron; copper; vitamins A, C, E, and B6; and folic acid have important influences on immune responses. Adequate intake of vitamins B6, folate, B12, C, E, and of selenium, zinc, copper, and iron supports a T helper cell (Th)1 cytokine-mediated immune response with sufficient production of proinflammatory cytokines, which maintains an effective immune response and avoids a shift to an anti-inflammatory Th2 cell-mediated immune response and an increased risk of extracellular infections. Supplementation with these micronutrients reverses the Th2 cell-mediated immune response to a proinflammatory Th1 cytokine-regulated response with enhanced innate immunity.
Reduxium, a dietary supplement that provides immune support, is a low-cost candidate to boost immune response. Reduxium is a natural compound commercialised in the USA that helps restore homeostasis and controls inflammation. As no toxins or allergens are used, but purely food grade compounds, it is classified as a dietary supplement. Its current purpose is not to treat, diagnose, prevent or cure any disease, but it has immunomodulatory properties. Reduxium is manufactured using a proprietary reactor - a "biochemical cavitation mixer" that allows to create a "smart small molecule". The principal device belongs to the cavitation technology family and is used for the intensification of technological processes in liquid media (liquid processing, splitting of complex molecules, "cold" pasteurization, destruction of solid inclusions). The usage of this process technology enables compression of a set of molecules to 1/12th their original size. Its components are: Phosphoric Acid (58%), Microelement Complex (33.6%) (Zinc, Copper, Iron Pyrophosphate, Potassium, Calcium, Silica, Glycyrrhizic Acid (8.4%). The Microelement Complex is made up of a homogenized complex with special indication, pH =0.0008-0.4, waterless in the final composition.The complex molecules generated scan at the cellular level for the presence of pathogenic (bacterial, viral, fungal) etiologies by reading the characteristics of the electron proton (KNa) pump on the membrane. If these characteristics are violated, the supplement "enters" the cell. At the intra-cellular level, the supplement scans the cell in search of pathology; this "scanning process" is made on the basis of selectivity (healthy - do not touch/ill - induce apoptosis) through the mechanism of mitochondria activity. Specifically, the complex molecules start a cascade of biochemical processes (switching to mitochondria aerobic oxidation, restarting the methyl group with the "epigenetic" effects on DNA, apoptosis). It is unclear how and to which extent this mechanism contributes to innate immune activation following cellular damage and stress, or how it contributes to the adaptive immune response of T and B cells. The primary objective is to analyse the changes in the immune responses after two weeks of Reduxium intake.The secondary objective is to analyse the safety and tolerability of Reduxium.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Reduxium 1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days |
Dietary Supplement: Reduxium
Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days.
|
Outcome Measures
Primary Outcome Measures
- Immune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium Intake [Baseline and weeks 3, 4, 5, 6, 7 and 8 post-baseline]
Blood tests of T cell subsets and phenotypes utilising groups of labelled antibodies
- Immune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium Intake [Baseline and weeks 3, 4, 5, 6, 7 and 8 post-baseline]
Blood tests of B cell subsets and phenotypes utilising groups of labelled antibodies
- Innate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium Intake [Baseline and weeks 3, 4, 5, 6, 7 and 8 post-baseline]
Blood tests of monocytes subsets utilising groups of labelled antibodies
- Innate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium Intake [Baseline and weeks 3, 4, 5, 6, 7 and 8 post-baseline]
Blood tests of NK cell subsets utilising groups of labelled antibodies
- Renal Panel (Sodium) After 2 Weeks of Reduxium Intake [Baseline and week 8 post-baseline]
Sodium blood tests
- Renal Panel (Potassium) After 2 Weeks of Reduxium Intake [Baseline and week 8 post-baseline]
Potassium blood tests
- Renal Panel (Urea) After 2 Weeks of Reduxium Intake [Baseline and week 8 post-baseline]
Urea blood tests
- Renal Panel (Creatinine) After 2 Weeks of Reduxium Intake [Baseline and week 8 post-baseline]
Creatinine blood tests
- Liver Panel (Aspartate Aminotransferase (AST)) After 2 Weeks of Reduxium Intake [Baseline and week 8 post-baseline]
AST blood tests
- Liver Panel (Alanine Aminotransferase (ALT)) After 2 Weeks of Reduxium Intake [Baseline and week 8 post-baseline]
ALT blood tests
- Liver Panel (Albumin) After 2 Weeks of Reduxium Intake [Baseline and week 8 post-baseline]
Albumin blood tests
- Liver Panel (Alkaline Phosphatase (ALP)) After 2 Weeks of Reduxium Intake [Baseline and week 8 post-baseline]
ALP blood tests
- Liver Panel (Bilirubin) After 2 Weeks of Reduxium Intake [Baseline and week 8 post-baseline]
Bilirubin blood tests
- Liver Panel (Lactate Dehydrogenase (LDH)) After 2 Weeks of Reduxium Intake [Baseline and week 8 post-baseline]
LDH blood tests
Secondary Outcome Measures
- Number of Adverse Events After Reduxium Intake [Baseline and weeks 3, 4, 5, 6, 7 and 8 post-baseline]
To analyse the safety and tolerability of Reduxium after 2 weeks of Reduxium intake, based on number of adverse events
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subjects of 21 - 50 years of age
-
Normal blood pressure (BP <140/90 nnHg)
-
Normal fasting glucose (<6mmol/L)
-
Subjects must stop all supplement for 1 month prior to enrolment
Exclusion Criteria:
-
Subjects with known history of lungs or cardiovascular disease
-
History of previous pancreatitis
-
Past or current history of malignancy
-
Subjects with type 2 diabetes
-
Past or current history of peptic ulcer disease
-
Current pregnancy or breastfeeding
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | National University of Singapore - The N.1 Institute for Health | Singapore | Singapore | 117456 | |
2 | National University of Singapore - Yong Loo Lin School of Medicine | Singapore | Singapore | 117597 | |
3 | National University Hospital | Singapore | Singapore | 119074 |
Sponsors and Collaborators
- Ogevity Therapeutics, Inc.
- National University, Singapore
Investigators
None specified.Study Documents (Full-Text)
More Information
Publications
- Chandra RK. Nutrition and the immune system: an introduction. Am J Clin Nutr. 1997 Aug;66(2):460S-463S. Review.
- Cui W, Fan Y, Wu W, Zhang F, Wang JY, Ni AP. Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome. Clin Infect Dis. 2003 Sep 15;37(6):857-9. Epub 2003 Aug 28.
- Li T, Qiu Z, Zhang L, Han Y, He W, Liu Z, Ma X, Fan H, Lu W, Xie J, Wang H, Deng G, Wang A. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J Infect Dis. 2004 Feb 15;189(4):648-51. Epub 2004 Feb 4.
- Wintergerst ES, Maggini S, Hornig DH. Contribution of selected vitamins and trace elements to immune function. Ann Nutr Metab. 2007;51(4):301-23. Epub 2007 Aug 28. Review.
- 0101.2006.0101.0001
Study Results
Participant Flow
Recruitment Details | Recruitment happened between October 7, 2020 and January 27, 2021 at National University Hospital (NUH) in Singapore. |
---|---|
Pre-assignment Detail |
Arm/Group Title | Reduxium |
---|---|
Arm/Group Description | 1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days Reduxium: Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days. |
Period Title: Overall Study | |
STARTED | 20 |
COMPLETED | 20 |
NOT COMPLETED | 0 |
Baseline Characteristics
Arm/Group Title | Reduxium |
---|---|
Arm/Group Description | The intervention consists of 1 oral drop of Reduxium (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days. |
Overall Participants | 20 |
Age (years) [Mean (Standard Deviation) ] | |
Mean (Standard Deviation) [years] |
32.4
(5.4)
|
Sex: Female, Male (Count of Participants) | |
Female |
14
70%
|
Male |
6
30%
|
Race and Ethnicity Not Collected (Count of Participants) | |
Region of Enrollment (Count of Participants) | |
Singapore |
20
100%
|
Outcome Measures
Title | Immune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium Intake |
---|---|
Description | Blood tests of T cell subsets and phenotypes utilising groups of labelled antibodies |
Time Frame | Baseline and weeks 3, 4, 5, 6, 7 and 8 post-baseline |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Reduxium |
---|---|
Arm/Group Description | The intervention consists of 1 oral drop of Reduxium (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days. |
Measure Participants | 20 |
Baseline - Total T cells |
60.53
(9.24)
|
Week 3 - Total T cells |
60
(10.27)
|
Week 4 - Total T cells |
59.29
(9.44)
|
Week 5 - Total T cells |
56.52
(11.88)
|
Week 6 - Total T cells |
57.44
(12.75)
|
Week 7 - Total T cells |
58.54
(10.23)
|
Week 8 - Total T cells |
58.54
(11.09)
|
Baseline - Total CD8 (cluster of differentiation 8)+ T cells |
34.08
(8.98)
|
Week 3 - Total CD8+ T cells |
35.08
(8.71)
|
Week 4 - Total CD8+ T cells |
35.08
(9.19)
|
Week 5 - Total CD8+ T cells |
34.46
(9.34)
|
Week 6 - Total CD8+ T cells |
35.30
(8.88)
|
Week 7 - Total CD8+ T cells |
34.68
(9.93)
|
Week 8 - Total CD8+ T cells |
34.49
(9.56)
|
Baseline - Exhausted CD8+ T cells |
1.81
(1.15)
|
Week 3 - Exhausted CD8+ T cells |
2.06
(1.42)
|
Week 4 - Exhausted CD8+ T cells |
2.03
(1.44)
|
Week 5 - Exhausted CD8+ T cells |
1.61
(1.00)
|
Week 6 - Exhausted CD8+ T cells |
1.78
(1.18)
|
Week 7 - Exhausted CD8+ T cells |
2.00
(1.36)
|
Week 8 - Exhausted CD8+ T cells |
1.88
(1.08)
|
Baseline - Total CD4+ cells |
54.16
(10.98)
|
Week 3 - Total CD4+ cells |
53.57
(12.13)
|
Week 4 - Total CD4+ cells |
53.97
(11.34)
|
Week 5 - Total CD4+ cells |
53.34
(12.22)
|
Week 6 - Total CD4+ cells |
53.58
(10.85)
|
Week 7 - Total CD4+ cells |
54.79
(12.30)
|
Week 8 - Total CD4+ cells |
54.49
(12.54)
|
Baseline - Exhausted CD4+ T cells |
11.30
(5.46)
|
Week 3 -Exhausted CD4+ T cells |
11.93
(5.39)
|
Week 4 -Exhausted CD4+ T cells |
11.15
(4.49)
|
Week 5 -Exhausted CD4+ T cells |
10.87
(5.96)
|
Week 6 -Exhausted CD4+ T cells |
10.65
(5.15)
|
Week 7 -Exhausted CD4+ T cells |
11.59
(5.76)
|
Week 8 -Exhausted CD4+ T cells |
11.27
(4.90)
|
Baseline -Regulatory T cells (Tregs) |
6.32
(1.39)
|
Week 3 - Regulatory T cells (Tregs) |
6.95
(1.50)
|
Week 4 - Regulatory T cells (Tregs) |
7.34
(1.80)
|
Week 5 - Regulatory T cells (Tregs) |
6.49
(1.93)
|
Week 6 - Regulatory T cells (Tregs) |
6.88
(1.90)
|
Week 7 - Regulatory T cells (Tregs) |
6.81
(1.90)
|
Week 8 - Regulatory T cells (Tregs) |
7.05
(1.53)
|
Baseline - chemokine receptor 3 (CXCR3)-Chemokine receptor 6 (CCR6)+ |
1.02
(1.45)
|
Week 3 - CXCR3-CCR6+ |
1.24
(2.24)
|
Week 4 - CXCR3-CCR6+ |
1.09
(1.81)
|
Week 5 - CXCR3-CCR6+ |
1.60
(2.23)
|
Week 6 - CXCR3-CCR6+ |
1.34
(1.94)
|
Week 7 - CXCR3-CCR6+ |
1.32
(1.92)
|
Week 8 - CXCR3-CCR6+ |
1.09
(1.63)
|
Baseline - T helper (Th) 1/Th17 cells |
7.17
(5.19)
|
Week 3 - Th1/Th17 cells |
6.02
(5.48)
|
Week 4 - Th1/Th17 cells |
5.33
(5.12)
|
Week 5 - Th1/Th17 cells |
4.55
(3.92)
|
Week 6 - Th1/Th17 cells |
4.57
(3.67)
|
Week 7 - Th1/Th17 cells |
4.70
(3.69)
|
Week 8 - Th1/Th17 cells |
4.56
(3.80)
|
Baseline - Th1 cells |
48.63
(24.93)
|
Week 3 - Th1 cells |
45.58
(30.23)
|
Week 4 - Th1 cells |
44.85
(31.63)
|
Week 5 - Th1 cells |
44.15
(31.98)
|
Week 6 - Th1 cells |
47.80
(33.09)
|
Week 7 - Th1 cells |
47.30
(30.82)
|
Week 8 - Th1 cells |
47.58
(32.12)
|
Baseline - Th17 cells |
1.28
(0.80)
|
Week 3 - Th17 cells |
1.16
(0.91)
|
Week 4 - Th17 cells |
1.21
(0.99)
|
Week 5 - Th17 cells |
1.19
(1.07)
|
Week 6 - Th17 cells |
1.16
(1.16)
|
Week 7 - Th17 cells |
1.14
(0.84)
|
Week 8 - Th17 cells |
1.24
(1.22)
|
Baseline - Th2 cells |
2.86
(1.75)
|
Week 3 - Th2 cells |
3.67
(2.28)
|
Week 4 - Th2 cells |
3.58
(2.13)
|
Week 5 - Th2 cells |
3.46
(1.97)
|
Week 6 - Th2 cells |
3.56
(1.94)
|
Week 7 - Th2 cells |
3.82
(2.33)
|
Week 8 - Th2 cells |
4.05
(2.23)
|
Baseline - T follicular helper cells (Tfh) |
13.75
(2.67)
|
Week 3 - T follicular helper cells (Tfh) |
12.75
(3.52)
|
Week 4 - T follicular helper cells (Tfh) |
12.02
(3.48)
|
Week 5 - T follicular helper cells (Tfh) |
12.40
(3.83)
|
Week 6 - T follicular helper cells (Tfh) |
12.22
(3.16)
|
Week 7 - T follicular helper cells (Tfh) |
12.33
(3.50)
|
Week 8 - T follicular helper cells (Tfh) |
11.58
(4.92)
|
Baseline - Activated Tfh (Inducible T-cell Costimulator (ICOS+)) |
0.50
(0.24)
|
Week 3 - Activated Tfh (ICOS+) |
0.45
(0.24)
|
Week 4 - Activated Tfh (ICOS+) |
0.44
(0.27)
|
Week 5 - Activated Tfh (ICOS+) |
0.38
(0.22)
|
Week 6 - Activated Tfh (ICOS+) |
0.40
(0.23)
|
Week 7 - Activated Tfh (ICOS+) |
0.47
(0.26)
|
Week 8 - Activated Tfh (ICOS+) |
0.48
(0.32)
|
Baseline - Activated Tfh (Programmed cell death protein 1 (PD-1+)) |
2.30
(0.84)
|
Week 3 - Activated Tfh (PD-1+) |
2.25
(0.88)
|
Week 4 - Activated Tfh (PD-1+) |
2.08
(1.01)
|
Week 5 - Activated Tfh (PD-1+) |
2.01
(0.85)
|
Week 6 - Activated Tfh (PD-1+) |
2.08
(0.85)
|
Week 7 - Activated Tfh (PD-1+) |
2.20
(0.91)
|
Week 8 - Activated Tfh (PD-1+) |
2.18
(1.16)
|
Baseline - Activated Tfh (ICOS+PD-1+) |
1.18
(0.67)
|
Week 3 - Activated Tfh (ICOS+PD-1+) |
1.17
(0.58)
|
Week 4 - Activated Tfh (ICOS+PD-1+) |
1.18
(0.60)
|
Week 5 - Activated Tfh (ICOS+PD-1+) |
1.00
(0.49)
|
Week 6 - Activated Tfh (ICOS+PD-1+) |
1.08
(0.46)
|
Week 7 - Activated Tfh (ICOS+PD-1+) |
1.32
(0.89)
|
Week 8 - Activated Tfh (ICOS+PD-1+) |
1.33
(0.84)
|
Title | Immune B Cell Subsets and Immunophenotype After 2 Weeks of Reduxium Intake |
---|---|
Description | Blood tests of B cell subsets and phenotypes utilising groups of labelled antibodies |
Time Frame | Baseline and weeks 3, 4, 5, 6, 7 and 8 post-baseline |
Outcome Measure Data
Analysis Population Description |
---|
healthy participants |
Arm/Group Title | Reduxium |
---|---|
Arm/Group Description | 1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days Reduxium: Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days. |
Measure Participants | 20 |
Baseline - Total B cells |
17.44
(6.89)
|
Week 3 - Total B cells |
21.09
(12.68)
|
Week 4 - Total B cells |
18.64
(7.32)
|
Week 5 - Total B cells |
19.84
(10.33)
|
Week 6 - Total B cells |
20.70
(9.28)
|
Week 7 - Total B cells |
20.48
(8.92)
|
Week 8 - Total B cells |
22.05
(10.99)
|
Baseline - Memory B cells (MBCs) |
7.47
(3.18)
|
Week 3 - Memory B cells (MBCs) |
7.34
(3.08)
|
Week 4 - Memory B cells (MBCs) |
7.63
(3.91)
|
Week 5 - Memory B cells (MBCs) |
7.44
(3.46)
|
Week 6 - Memory B cells (MBCs) |
7.17
(2.93)
|
Week 7 - Memory B cells (MBCs) |
7.53
(3.38)
|
Week 8 - Memory B cells (MBCs) |
7.66
(3.68)
|
Baseline - Classical MBCs |
1.24
(0.78)
|
Week 3 - Classical MBCs |
0.96
(0.55)
|
Week 4 - Classical MBCs |
1.06
(0.69)
|
Week 5 - Classical MBCs |
1.15
(0.60)
|
Week 6 - Classical MBCs |
0.90
(0.48)
|
Week 7 - Classical MBCs |
0.91
(0.53)
|
Week 8 - Classical MBCs |
0.93
(0.57)
|
Baseline - Activated MBCs |
6.28
(2.78)
|
Week 3 - Activated MBCs |
6.37
(2.79)
|
Week 4 - Activated MBCs |
6.59
(3.69)
|
Week 5 - Activated MBCs |
6.46
(3.15)
|
Week 6 - Activated MBCs |
6.25
(2.69)
|
Week 7 - Activated MBCs |
6.61
(3.09)
|
Week 8 - Activated MBCs |
6.71
(3.38)
|
Baseline - Tissue-like MBCs |
1.27
(0.90)
|
Week 3 - Tissue-like MBCs |
1.01
(0.62)
|
Week 4 - Tissue-like MBCs |
1.09
(0.69)
|
Week 5 - Tissue-like MBCs |
1.04
(0.63)
|
Week 6 - Tissue-like MBCs |
0.96
(0.56)
|
Week 7 - Tissue-like MBCs |
0.95
(0.54)
|
Week 8 - Tissue-like MBCs |
0.99
(0.60)
|
Baseline - Switched B cells |
1.58
(1.24)
|
Week 3 - Switched B cells |
1.23
(1.21)
|
Week 4 - Switched B cells |
1.39
(1.21)
|
Week 5 - Switched B cells |
1.33
(1.12)
|
Week 6 - Switched B cells |
1.17
(1.06)
|
Week 7 - Switched B cells |
1.35
(1.13)
|
Week 8 - Switched B cells |
1.75
(2.15)
|
Baseline - Unswitched B cells |
7.96
(3.37)
|
Week 3 - Unswitched B cells |
7.76
(3.26)
|
Week 4 - Unswitched B cells |
8.16
(4.27)
|
Week 5 - Unswitched B cells |
7.90
(3.60)
|
Week 6 - Unswitched B cells |
7.58
(3.07)
|
Week 7 - Unswitched B cells |
7.98
(3.52)
|
Week 8 - Unswitched B cells |
8.11
(3.83)
|
Baseline - Naïve B cells |
4.74
(2.61)
|
Week 3 - Naïve B cells |
5.13
(3.00)
|
Week 4 - Naïve B cells |
5.02
(3.02)
|
Week 5 - Naïve B cells |
4.85
(3.07)
|
Week 6 - Naïve B cells |
4.97
(3.10)
|
Week 7 - Naïve B cells |
5.28
(3.18)
|
Week 8 - Naïve B cells |
5.55
(3.41)
|
Baseline - Plasmablasts |
5.38
(3.63)
|
Week 3 - Plasmablasts |
4.67
(3.79)
|
Week 4 - Plasmablasts |
4.85
(3.68)
|
Week 5 - Plasmablasts |
5.12
(3.89)
|
Week 6 - Plasmablasts |
4.66
(3.53)
|
Week 7 - Plasmablasts |
4.21
(3.08)
|
Week 8 - Plasmablasts |
4.33
(3.26)
|
Baseline - Exhausted B cells |
3.13
(1.83)
|
Week 3 - Exhausted B cells |
2.36
(1.48)
|
Week 4 - Exhausted B cells |
2.68
(1.88)
|
Week 5 - Exhausted B cells |
2.71
(1.50)
|
Week 6 - Exhausted B cells |
2.25
(1.22)
|
Week 7 - Exhausted B cells |
2.45
(1.33)
|
Week 8 - Exhausted B cells |
2.83
(2.31)
|
Title | Innate Immune Cell Subsets (Monocytes -Cluster of Differentiation 14 R-Phycoerythrin (CD14PE)) After 2 Weeks of Reduxium Intake |
---|---|
Description | Blood tests of monocytes subsets utilising groups of labelled antibodies |
Time Frame | Baseline and weeks 3, 4, 5, 6, 7 and 8 post-baseline |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Reduxium |
---|---|
Arm/Group Description | 1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days Reduxium: Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days. |
Measure Participants | 20 |
Baseline - Non-classical monocytes |
4.88
(3.41)
|
Week 3 - Non-classical monocytes |
2.50
(1.84)
|
Week 4 - Non-classical monocytes |
2.99
(2.01)
|
Week 5 - Non-classical monocytes |
2.94
(2.15)
|
Week 6 - Non-classical monocytes |
2.51
(2.04)
|
Week 7 - Non-classical monocytes |
2.73
(1.80)
|
Week 8 - Non-classical monocytes |
3.26
(1.68)
|
Baseline - Intermediate monocytes |
7.26
(7.17)
|
Week 3 - Intermediate monocytes |
4.00
(5.63)
|
Week 4 - Intermediate monocytes |
5.60
(5.60)
|
Week 5 - Intermediate monocytes |
5.79
(7.20)
|
Week 6 - Intermediate monocytes |
5.41
(6.23)
|
Week 7 - Intermediate monocytes |
6.08
(6.32)
|
Week 8 - Intermediate monocytes |
7.49
(7.31)
|
Baseline - Classical monocytes |
78.92
(11.78)
|
Week 3 - Classical monocytes |
84.86
(8.92)
|
Week 4 - Classical monocytes |
83.27
(9.06)
|
Week 5 - Classical monocytes |
83.68
(10.25)
|
Week 6 - Classical monocytes |
85.39
(8.31)
|
Week 7 - Classical monocytes |
84.87
(8.45)
|
Week 8 - Classical monocytes |
82.72
(10.86)
|
Title | Innate Immune Cell Subsets [Natural Killer (NK) Cells (CD56 Allophycocyanin (APC)] After 2 Weeks of Reduxium Intake |
---|---|
Description | Blood tests of NK cell subsets utilising groups of labelled antibodies |
Time Frame | Baseline and weeks 3, 4, 5, 6, 7 and 8 post-baseline |
Outcome Measure Data
Analysis Population Description |
---|
healthy participants. |
Arm/Group Title | Reduxium |
---|---|
Arm/Group Description | 1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days Reduxium: Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days. |
Measure Participants | 20 |
CD16++CD56- - Baseline |
0.89
(0.62)
|
Week 3 - CD16++CD56- |
0.91
(0.50)
|
Week 4 - CD16++CD56- |
0.99
(0.44)
|
Week 5 - CD16++CD56- |
0.83
(0.39)
|
Week 6 - CD16++CD56- |
1.02
(0.58)
|
Week 7 - CD16++CD56- |
1.24
(0.60)
|
Week 8 - CD16++CD56- |
1.34
(0.56)
|
Baseline - CD16+CD56+ |
67.89
(13.20)
|
Week 3 - CD16+CD56+ |
66.63
(15.26)
|
Week 4 - CD16+CD56+ |
66.31
(15.48)
|
Week 5 - CD16+CD56+ |
67.07
(15.67)
|
Week 6 - CD16+CD56+ |
69.92
(13.13)
|
Week 7 - CD16+CD56+ |
69.86
(10.90)
|
Week 8 - CD16+CD56+ |
69.04
(13.01)
|
Baseline - CD16+CD56++ |
0.94
(0.47)
|
Week 3 - CD16+CD56++ |
1.09
(0.68)
|
Week 4 - CD16+CD56++ |
0.96
(0.45)
|
Week 5 - CD16+CD56++ |
0.90
(0.42)
|
Week 6 - CD16+CD56++ |
1.08
(0.59)
|
Week 7 - CD16+CD56++ |
1.06
(0.45)
|
Week 8 - CD16+CD56++ |
1.23
(0.68)
|
Baseline - CD16-CD56+ |
2.05
(1.01)
|
Week 3 - CD16-CD56+ |
1.78
(0.98)
|
Week 4 - CD16-CD56+ |
1.68
(0.69)
|
Week 5 - CD16-CD56+ |
1.68
(0.84)
|
Week 6 - CD16-CD56+ |
1.61
(0.73)
|
Week 7 - CD16-CD56+ |
1.66
(0.73)
|
Week 8 - CD16-CD56+ |
1.56
(0.84)
|
Baseline - CD16-CD56++ |
2.98
(1.54)
|
Week 3 - CD16-CD56++ |
2.90
(1.60)
|
Week 4 - CD16-CD56++ |
2.66
(1.23)
|
Week 5 - CD16-CD56++ |
2.61
(1.26)
|
Week 6 - CD16-CD56++ |
2.84
(1.44)
|
Week 7 - CD16-CD56++ |
2.67
(1.06)
|
Week 8 - CD16-CD56++ |
3.16
(1.79)
|
Title | Renal Panel (Sodium) After 2 Weeks of Reduxium Intake |
---|---|
Description | Sodium blood tests |
Time Frame | Baseline and week 8 post-baseline |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Reduxium |
---|---|
Arm/Group Description | 1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days Reduxium: Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days. |
Measure Participants | 20 |
Baseline |
139.55
(1.43)
|
Week 8 |
139.40
(1.59)
|
Title | Renal Panel (Potassium) After 2 Weeks of Reduxium Intake |
---|---|
Description | Potassium blood tests |
Time Frame | Baseline and week 8 post-baseline |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Reduxium |
---|---|
Arm/Group Description | 1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days Reduxium: Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days. |
Measure Participants | 20 |
Baseline |
4.26
(0.49)
|
Week 8 |
4.54
(0.46)
|
Title | Renal Panel (Urea) After 2 Weeks of Reduxium Intake |
---|---|
Description | Urea blood tests |
Time Frame | Baseline and week 8 post-baseline |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Reduxium |
---|---|
Arm/Group Description | 1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days Reduxium: Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days. |
Measure Participants | 20 |
Baseline |
4.20
(1.45)
|
Week 8 |
4.04
(1.08)
|
Title | Renal Panel (Creatinine) After 2 Weeks of Reduxium Intake |
---|---|
Description | Creatinine blood tests |
Time Frame | Baseline and week 8 post-baseline |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Reduxium |
---|---|
Arm/Group Description | 1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days Reduxium: Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days. |
Measure Participants | 20 |
Baseline |
69.05
(12.09)
|
Week 8 |
68.85
(11.76)
|
Title | Liver Panel (Aspartate Aminotransferase (AST)) After 2 Weeks of Reduxium Intake |
---|---|
Description | AST blood tests |
Time Frame | Baseline and week 8 post-baseline |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Reduxium |
---|---|
Arm/Group Description | 1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days Reduxium: Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days. |
Measure Participants | 20 |
Baseline |
19.50
(3.35)
|
Week 8 |
20.55
(4.15)
|
Title | Liver Panel (Alanine Aminotransferase (ALT)) After 2 Weeks of Reduxium Intake |
---|---|
Description | ALT blood tests |
Time Frame | Baseline and week 8 post-baseline |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Reduxium |
---|---|
Arm/Group Description | 1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days Reduxium: Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days. |
Measure Participants | 20 |
Baseline |
15.90
(7.66)
|
Week 8 |
17.40
(9.45)
|
Title | Liver Panel (Albumin) After 2 Weeks of Reduxium Intake |
---|---|
Description | Albumin blood tests |
Time Frame | Baseline and week 8 post-baseline |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Reduxium |
---|---|
Arm/Group Description | 1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days Reduxium: Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days. |
Measure Participants | 20 |
Baseline |
42.80
(3.37)
|
Week 8 |
42.95
(2.03)
|
Title | Liver Panel (Alkaline Phosphatase (ALP)) After 2 Weeks of Reduxium Intake |
---|---|
Description | ALP blood tests |
Time Frame | Baseline and week 8 post-baseline |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Reduxium |
---|---|
Arm/Group Description | 1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days Reduxium: Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days. |
Measure Participants | 20 |
Baseline |
62.90
(19.82)
|
Week 8 |
59.90
(15.87)
|
Title | Liver Panel (Bilirubin) After 2 Weeks of Reduxium Intake |
---|---|
Description | Bilirubin blood tests |
Time Frame | Baseline and week 8 post-baseline |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Reduxium |
---|---|
Arm/Group Description | 1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days Reduxium: Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days. |
Measure Participants | 20 |
Baseline |
11.90
(4.09)
|
Week 8 |
11.25
(3.50)
|
Title | Liver Panel (Lactate Dehydrogenase (LDH)) After 2 Weeks of Reduxium Intake |
---|---|
Description | LDH blood tests |
Time Frame | Baseline and week 8 post-baseline |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Reduxium |
---|---|
Arm/Group Description | 1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days Reduxium: Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days. |
Measure Participants | 20 |
Baseline |
310.80
(43.87)
|
Week 8 |
377
(108.54)
|
Title | Number of Adverse Events After Reduxium Intake |
---|---|
Description | To analyse the safety and tolerability of Reduxium after 2 weeks of Reduxium intake, based on number of adverse events |
Time Frame | Baseline and weeks 3, 4, 5, 6, 7 and 8 post-baseline |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Reduxium |
---|---|
Arm/Group Description | 1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days Reduxium: Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days. |
Measure Participants | 20 |
Number [adverse events] |
0
|
Adverse Events
Time Frame | 8 weeks | |
---|---|---|
Adverse Event Reporting Description | ||
Arm/Group Title | Reduxium | |
Arm/Group Description | 1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days Reduxium: Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days. | |
All Cause Mortality |
||
Reduxium | ||
Affected / at Risk (%) | # Events | |
Total | 0/20 (0%) | |
Serious Adverse Events |
||
Reduxium | ||
Affected / at Risk (%) | # Events | |
Total | 0/20 (0%) | |
Other (Not Including Serious) Adverse Events |
||
Reduxium | ||
Affected / at Risk (%) | # Events | |
Total | 0/20 (0%) |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
Results Point of Contact
Name/Title | Study administrator |
---|---|
Organization | NUS |
Phone | +65 6601 7766 |
lsixtc@nus.edu.sg |
- 0101.2006.0101.0001